Our Story

Currently. . . 

ThermaSolutions is the global leader in Hyperthermic Medical Technology. We have established and will continue our leadership through extensive research, development and product innovation.

ThermaSolutions manufactures and distributes the ThermoChem™ HT family of systems and customized procedure kits and disposables to assist in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) procedures.

ThermaSolutions provides direct sales, service and support in the United States with our partner Genesis Medical Group (GMG) and through a well-established distribution network, internationally.  The HT-2000 and HT-2500 devices are utilized in more than 300 Oncology Centers throughout the United States, Europe, Latin America, Australia/New Zealand, Middle East, Africa, and Asia.

ThermaSolutions is also proud to be one of the pioneers in aerosolization liquids during minimally invasive procedures.  Our HurriChem device is the first to achieve both CE and FDA approval  See the product pages for uses in your area of the world.

US:  HurriChem US

Rest of the world: HurriChem CE

How We Got Here. . .

ThermaSolutions traces a history back to 2003 with the acquisition of ViaCirq, Inc. Prior to the acquisition, ViaCirq had obtained the first FDA cleared device specifically designed for HIPEC in December 1999. The ThermoChem™ HT-1000 was the first generation of a fully integrated system specifically designed and manufactured for delivering intraperitoneal hyperthermia (IPH). Since 2003, ThermaSolutions has been the market leader in the development and advancement of Hyperthermic Intraperitoneal Chemotherapy (HIPEC). The ThermoChem™ HT-1000 device, was introduced at the 54th Annual Cancer Symposium and Exhibition meeting of the Society of Surgical Oncology Symposium in Washington, DC on March 16, 2001. Instrumental in the history of ThermaSolutions was the 2012 acquisition of the company by the Dutch ter Stege family (Willem and Lenie) as company growth has been greatly influenced by their vision and business operations. Since then, the ThermaSolutions product line has evolved to subsequent generations of the ThermoChem™ devices (HT-2000 and HT-2500) and a complete line of HIPEC Procedure Kits and Disposables. Genesis Medical Group (GMG), represented by Glenn and Gary Keeling, have been business affiliates for almost the entire history of ThermaSolutions.  Glenn and Gary and Mark Toto of GMG have a history in HIPEC that goes back to 1999 and have provided ThermaSolutions with a large presence in the United States. Our close harmony with these and other dedicated experts have brought the company to where it is today; poised for a bright future.

ThermaSolutions and HIPEC. . . 

Cytoreductive surgery (CRS) for tumor debulking has been practiced since the 1930s and techniques continued to advance during subsequent decades¹. In the 1980s, research indicated hyperthermia plus intraperitoneal chemotherapy was effective to combat cancer cells after the first HIPEC ever was performed in 1979. A 47-year-old Japanese patient was treated by Dr. John Spratt from The University of Louisville, Kentucky in a groundbreaking event¹. Paul Sugarbaker at the Washington Cancer Institute followed with favorable survival benefits with this exciting therapy² and in 1995, he reported a protocols for CRS + HIPEC.³ This treatment has become standard of care; especially since Dr. Vic Verwaal’s study in 2003 showing HIPEC as a regional cancer treatment as more effective than systemic chemotherapy.4 Over the years, techniques for CRS and HIPEC have included development of the open “Coliseum”, closed, semi-closed, and laparoscopic surgical methods¹. ThermaSolutions was an active participant in the early years of the development and advancement of HIPEC.

Who we are:

ThermaSolutions manufactures and sells devices for regional cancer treatment including Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC), Hyperthermic Intraperitoneal Chemotherapy (HIPEC), Isolated Limb, Whole Body Hyperthermia, and specialized products within cancer care.

Cancers treated:

  • Pseudomyxoma Peritonei – A build-up of mucin in the peritoneal cavity
  • Ovarian Carcinoma – Cancer that forms in the tissue of the ovary
  • Mucinous Adenocarcinoma of Appendix  – A type of cancer that begins in cells that line the appendix and produces mucin
  • Gastric Carcinoma – Cancer that forms in tissues lining the stomach
  • Colorectal Carcinoma – Cancer that forms in the colon
  • Mesothelioma  – A benign (noncancerous) or malignant (cancerous) tumor affecting the lining of the chest or abdomen
  • Low-Grade Sarcoma – Sarcoma is a cancer of the bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue

We train medical staff on the ThermaSolutions devices and sterile disposables with unparalleled customer service and support.

ThermaSolutions has been intricately and consistently involved in cancer treatment since 1995, partnering with physicians world-wide in 6 continents and over 50 countries.


1. Neuwirth, Madalyn G.; Alexander, H. Richard; Karakousis, Giorgos C. (2016-02-01). “Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective”. Journal of Gastrointestinal Oncology. 7(1): 18–28. doi:10.3978/j.issn.2078-6891.2015.106. ISSN 2078-6891. PMC 4754315. PMID 26941981.
2. Sugarbaker, P. H. (1988-01-01). “Surgical management of peritoneal carcinosis: diagnosis, prevention and treatment”. Langenbecks Archiv für Chirurgie. 373 (3): 189–196. doi:10.1007/bf01274232. ISSN 0023-8236. PMID 3288830. S2CID 22833013.
3. Sugarbaker, P. H. (1995-01-01). “Peritonectomy procedures”. Annals of Surgery. 221 (1): 29–42. doi:10.1097/00000658-199501000-00004. ISSN 0003-4932. PMC 1234492. PMID 7826158.
4 Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003 Oct 15;21(20):3737-43. doi: 10.1200/JCO.2003.04.187. PMID: 14551293.

[/col] [/row] [/section]